Life Sciences Today

Danny Lieberman and John Lynn

The Life Sciences Today podcast by Healthcare IT Today brings you strategic conversations with life science founders. Hosts Danny Lieberman and John Lynn and their guests reveal the patterns behind sustainable competitive advantages. Subscribe to the Clear Thinking newsletter by Danny Lieberman for deeper pattern analysis.

  1. 3d ago

    Evogene - Can a Platform Company Become a Real Business?

    We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Gabi Tarcic, Chief Development Officer at Evogene. In this episode, I sit down with Tarcic to ask a question the industry has been asking for twenty years: how does a platform company become a real business? Evogene has lived through every wave of “compute will transform biology” — genomics, systems biology, computational biology platforms, and now generative AI — and built a business across human health, medical cannabis, and agriculture on the bet that the answer is yes.  A must-listen for TechBio founders. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: What does Evogene actually do, and what does BD look like in a company structured around a computational platform and multiple subsidiaries? The company has lived through several waves of “compute will transform biology” — genomics, systems biology, computational biology platforms, and now generative AI. What’s genuinely different about this wave, and what’s the same story in new packaging? Platform companies struggle to monetize because value accrues to the products, not the platform. Evogene has tried both — licensing the tech engines out and spinning up subsidiaries to develop products in-house. What have you learned about which model actually works? In a world where AlphaFold is free, foundation models are commoditized, and every biotech now claims to be AI-driven — what’s defensible about Evogene’s platform that a well-funded startup with the latest models can’t replicate? You’re in BD, which means you’re the one sitting across the table from potential partners who have to decide whether Evogene’s platform is a genuine accelerator or just another vendor. What do the good conversations have in common, and where do the deals that fall apart usually fall apart? What’s the biggest anti-pattern you see in TechBio — something founders and platform companies keep doing that doesn’t work, that everyone in the industry has watched play out multiple times now? Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

  2. Aug 7

    How TheraNow Scales Physical Therapy Without New Clinics

    We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Dr. Ashok Gupta, Founder and CEO at TheraNow. In this episode, I speak with Dr. Gupta about why the real bottleneck in physical therapy isn’t quality — it’s access. Dr. Gupta explains how TheraNow built a virtual physical therapy model that helps health systems expand capacity without adding buildings or staff, and why 99% of the company’s revenue now comes from hospitals and their outpatient networks. Our conversation covers the shift from pre-COVID resistance to post-COVID reimbursement, the operational moat created by combining software with a 39-state clinician network, and why fragmented tools fail when they don’t fit clinical workflows.  We also dig into a core industry anti-pattern: putting care in the wrong physical location, where even parking and travel time become barriers to treatment. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: Tell me about your personal journey – how did you end up in this? You have different kinds of customers—individual clinics, healthcare plans, healthcare providers— so how do you create value? Is compliance better or worse when you operate online? I saw on your website you have four different kinds of customers. Out of the four, where do you make the most money? Considering that you’re not the only person with this idea, what is your moat? Are the physical therapists who work for you on your payroll, or are they contractors? What are three things you want to do for your customers, which are healthcare/hospital systems, in the next twelve months? What are three things you want to do for your customers in the next twelve months? What is the biggest anti-pattern in the industry? Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

  3. Jul 31

    How to Get 7 Figure Savings in Clinical Trials Without AI

    We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Dr. Jurate Lusienne, Clinical Trial Optimization at Jura Lasas Consulting. Lusienne helps small biotechs run early clinical trials faster, cheaper, and with more control—without relying on big CROs or fancy AI.  Drawing on experience across academia, CROs, and sponsor-side clinical ops in the US, Japan, UK, and Lithuania, she explains how founders can avoid expensive default decisions and design leaner, smarter trial strategies. We discuss how small teams can save 30–60% on Phase 1 and 2 trials, why sponsors remain responsible under GCP no matter who they outsource to, and the industry anti-pattern she sees most often: small biotechs choosing large CROs for a false sense of safety. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: Tell me about your personal journey – how did you end up doing what you’re doing? How do you create value for a biotech? The decisions we make in life science companies today— whether it’s in the clinical journey or before that in the application or scientific side— tend to be ingrained in the minds of the Founder and CEO: ‘this is what I have to do.’ This brings them to a point where years down the line, they’ve lost their optionality. Do you agree with that, or is that something that you think is just highly exaggerated on social media? How do you add value? What do you get people to do? Let’s say I’m a small biotech and I got a quote from a big CRO. How much could I expect to save in terms of time and money if I worked with you? What is your business model? Why would a biotech want to work with a big CRO instead of working with you? What are three things you want to do for your customers in the next twelve months? What is the biggest anti-pattern in your industry today? To what degree is it about learning for the biotech? When you outsource everything to a big CRO, it seems to me that the chances of a small biotech learning something new are kind of small. So maybe the secret sauce is that you’re actually helping these small biotechs learn a lot faster. Is that true? Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

  4. Jul 24

    Breaking Clinical Data Chaos

    We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Raj Indupuri, Co-Founder and CEO at eClinical Solutions. Why is clinical development still run like a sequence of handoffs instead of a continuous learning system? In this episode, I talk with Indupuri about the industry’s biggest anti-pattern: milestone-based, sequential trials. We discuss clinical data chaos, AI in regulated environments, the real moat behind trusted execution, and how sponsors are starting to treat clinical data as core IP. We also dig into switching costs, CRO channel conflict, and what Indupuri says eClinical will deliver for customers over the next 12 months: faster cycle times, less manual work, and more agile decision-making. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: What’s the biggest anti-pattern in the industry? Tell me about your personal journey. How do you create value? How do you capture value? You work with sponsors and CROs – how do you handle channel conflict? What is your moat? What does a greenfield competitor building this today get right that you can’t? What are three things you are going to do for your customers in the next twelve months? Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

  5. Jul 17

    Using AI to Reduce Biostatistical Analysis Readouts

    We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Kyle McBride, VP, AI Innovation at Veristat. We talked about InStat, the clinical research industry’s first zero-code, fully automated biostatistics solution, reducing manual effort to speed time to approval with every output backed by validated statistical engines and expert biostatistician review. It delivers submission-ready tables, listings, and figures (TLF) in five days or less*, rather than the four to six weeks that sponsors typically wait after database lock, while maintaining the highest-quality data. McBride has taken a first-principles approach to designing the software components to fully automate biostatistics in clinical trials using AI. We spoke about the gap between AI demos and AI that actually ships in regulated environments, the economics of CRO delivery in an AI-native world, and the operational realities of running an AI transformation inside a 20-year-old CRO. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: Tell me about your journey. How did you end up doing what you do now? What’s the value creation in AI-augmented biostatistics? How do you capture value? What is your moat? Are you still using SDTM? What are three things you want to do for your customers in 2026? What’s the biggest anti-pattern in the industry? Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

  6. Jul 10

    Why the Industry You've Never Heard Of Is About to Change Hands

    We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Rachel Timberlake, Director of Business Development, Bend Bioscience. Contract manufacturing is a ~$275B global industry most people outside pharma have never heard of. Every drug you’ve ever taken and most of the medical devices you’ve ever used were made, at least in part, by a CDMO — a Contract Development and Manufacturing Organization — that your doctor, your pharmacist, and usually the drug company’s own marketing team will never mention. For the last decade, these businesses have been quietly rolled up by private equity, and 2026 is shaping up to be the year the ZIRP-era platforms either exit well, exit badly, or get absorbed into something bigger. Timberlake has spent two decades inside this industry. She started at a small owner-operated CDMO doing — in her words — “chief cook and bottle washer” work and moved through roles of increasing scale into national sales leadership. Timberlake is one of the few people who can explain this industry in plain language — she has lived every altitude of it, from small-shop BD to national sales leadership inside a large platform, and she is now choosing what comes next. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: What is a CDMO? What does a sponsor actually buy, and why doesn’t every drug or device company just build its own factory? Chief cook and bottle washer to national sales — what did a small CDMO look like when you started, and what did business development actually mean back then? When a biotech CEO calls a CDMO for the first time, what does the first ninety days actually look like — and where does it most often go sideways? Onshoring is the tailwind everyone is talking about — BIOSECURE, tariffs, GLP-1 capacity. What are you actually seeing in the RFPs? What should a founder ask a CDMO in diligence that most of them don’t think to ask? What is the biggest anti-pattern you see at the sponsor–CDMO interface? What’s the kind of problem you’d most want to work on next? Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

  7. Jul 3

    The Kids Nobody Builds For: Why Pediatrics is the Hardest Problem

    We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Dr. Darren Klugman, Founder at Alumni Ventures. In this episode, Klugman and I confront the most uncomfortable truth in life sciences — that the financial model gates the science, and the patients who need innovation most (children) are the ones the market systematically ignores. Klugman brings the clinician’s view from the CICU, the quality leader’s view from Johns Hopkins, and the founder’s view from a company he’s building to fix what’s broken in pediatric care. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: You went from Emory undergrad to Drexel master’s to GWU med school to Children’s National to Johns Hopkins CICU director. That’s a very deliberate path into one of the hardest corners of medicine. What was the moment that locked you in — and what does 20 years in pediatric cardiac critical care do to how you see the life sciences industry? You told me that data, stakeholder alignment, adoption, and reimbursement are all tightly intertwined — pull one thread and the whole thing unravels. In your experience running quality and safety programs across institutions, what does it actually look like when a clinical innovation gets all of those things right? What’s the anatomy of a win? How are you thinking about value capture in pediatrics, where the market is structurally small and the patients are the most vulnerable?  If you could move three needles this year — for the kids in your CICU, for the physicians trying to care for them, or for the system that’s supposed to support both — what are they? You said it plainly: the financial model gates the science, and pediatrics pays the price because there’s no big enough TAM. Is that the anti-pattern — or is there something deeper underneath it? And what does the fix actually require? Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

  8. Jun 26

    Enriching Psychiatric Evaluations with AI

    We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Iris Shtein, Co-Founder and CEO at Mentaily. Due to limited resources and social misconceptions, only 44% of US adults are receiving the treatment they need. Patients endure long wait times due to traditional intake processes. Mentaily – a patented AI model – creates diagnostic intelligence with almost perfect accuracy by the DSM gold standard, before the patient’s first engagement with a clinician. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: Tell us about your journey. What does Mentaily do? Who are your customers? What’s your moat? What’s your superpower? What’s the business model? How do you capture value? What is the biggest anti-pattern in your industry today? Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

About

The Life Sciences Today podcast by Healthcare IT Today brings you strategic conversations with life science founders. Hosts Danny Lieberman and John Lynn and their guests reveal the patterns behind sustainable competitive advantages. Subscribe to the Clear Thinking newsletter by Danny Lieberman for deeper pattern analysis.

You Might Also Like